Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting the Tumor-associated Antigens NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE in Patients With Advanced Melanoma

NCT02410733 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT02410733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02410733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting the Tumor-associated Antigens NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE in Patients With Advanced Melanoma
Lead sponsor
BioNTech SE
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
June 20, 2023
Enrollment
119 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma